
See PYLARIFY® data in patients with high-risk PCa who were candidates for initial definitive therapy
Learn MoreNot actual patients.
*Category 2A recommendations are made when based upon lower-level evidence there is uniform NCCN consensus that the intervention is appropriate.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
PET IMAGING:
FOR ACCURACY5
PSMA TARGETING:
FOR PRECISION6-8
18F RADIOISOTOPE:
FOR CLARITY4
ARTIFICIAL INTELLIGENCE:
FOR CONSISTENCY1
This combination brings superior diagnostic performance in assessing patients with suspected metastasis for initial definitive therapy† or suspected recurrence based on elevated PSA,‡ allowing you to better assess your patients' disease status.2,4,5,9
†Compared to standard anatomic images.12
‡In the setting of negative or equivocal standard imaging.13
See PYLARIFY® data in patients with high-risk PCa who were candidates for initial definitive therapy
Learn More
The incidence of prostate cancer is rising and
resulting mortality rates remain significant14,15
new prostate cancer cases will be diagnosed in 202214,15
deaths will occur in 2022 due to PCa, the second leading cause of cancer death in American men14,15
5-year relative survival rate for patients diagnosed with localized prostate cancer approaches 100%, however, if distant metastasis is present at the time of diagnosis, the 5-year survival rate has been reported to be 32%18
Standard imaging offers limited accuracy in PCa assessment, potentially compromising therapeutic decision-making19,20
§With an appropriate tracer and combined with CT or MRI.
which reduces the risk of undertreatment (leading to disease spread) and overtreatment (leading to unnecessary toxicity or surgery)23,24
LEARN ABOUT PYLARIFY®CT=computed tomography; MRI=magnetic resonance imaging; NCCN=National Comprehensive Cancer Network; PCa=prostate cancer; PET=positron emission tomography; PSMA=prostate-specific membrane antigen.
INDICATION & IMPORTANT
SAFETY INFORMATION
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
References